Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading Volume - Time to Buy?

Key Points

• Q4/FY2025 results beat expectations — Zevra reported revenue of $34.13M and GAAP EPS of $0.19, with commercial uptake of Miplyffa driving revenue and a new diagnostic partnership with GeneDx expected to boost patient identification and therapy demand.
• Market reaction and risks are mixed — shares saw unusually high trading volume (≈1.29M, +20%) and traded down ~9.6% amid significant insider selling (114,158 shares in the last 90 days) and near‑term EPS cuts from HC Wainwright, even as several analysts maintain buy ratings and $23–$26 price targets.

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) saw an uptick in trading volume on Wednesday . 1,288,747 shares changed hands during trading, an increase of 20% from the previous session's volume of 1,069,613 shares.The stock last traded at $9.8550 and had previously closed at $11.06.

More Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Zevra reported strong Q4/FY2025 results — revenue of $34.13M and GAAP EPS of $0.19, both above expectations; the quarter and conference call reinforced that Miplyffa is driving commercial revenue. Q4 Earnings & Transcript
• Positive Sentiment: Third‑party coverage highlights rapid Miplyffa adoption in the ultra‑rare Niemann‑Pick C market and argues the drug validates Zevra’s rare‑disease commercial model — a bullish narrative for revenue sustainability if payor coverage and diagnostics expansion continue. Seeking Alpha: Miplyffa Uptake
• Positive Sentiment: Zevra announced a diagnostic partnership with GeneDx to launch genetic testing support for suspected Niemann‑Pick C patients — this can increase case identification and downstream therapy demand. GeneDx Program
• Neutral Sentiment: Media coverage and investor materials emphasize optimism around potential EMA approval for the Niemann‑Pick C treatment, which would be a material upside if realized but remains uncertain. MSN: EMA Optimism
• Negative Sentiment: HC Wainwright cut EPS forecasts across FY2026–FY2028 (FY2026 to $0.23 from $0.29; FY2027 to $1.16 from $1.34; FY2028 to $1.75 from $2.00) and set Q3‑2026 at $0.08 — these downgrades lowered near‑term expectations and likely pressured the stock despite the recent beat. Analyst Estimate Changes

Analyst Upgrades and Downgrades

ZVRA has been the topic of a number of analyst reports. HC Wainwright set a $26.00 price target on shares of Zevra Therapeutics in a research report on Tuesday, December 30th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Zevra Therapeutics in a research note on Friday, January 9th. Finally, Guggenheim set a $23.00 target price on shares of Zevra Therapeutics and gave the stock a "buy" rating in a report on Tuesday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Zevra Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $23.00.

Zevra Therapeutics Trading Down 9.6%

The company has a current ratio of 8.62, a quick ratio of 8.57 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $562.66 million, a P/E ratio of 7.52 and a beta of 0.91. The business has a 50 day moving average of $8.85 and a 200-day moving average of $9.07.

Insider Activity at Zevra Therapeutics

In related news, insider Adrian W. Quartel sold 4,533 shares of the business's stock in a transaction on Friday, January 30th. The shares were sold at an average price of $8.83, for a total value of $40,026.39. Following the sale, the insider directly owned 9,723 shares of the company's stock, valued at approximately $85,854.09. The trade was a 31.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Joshua Schafer sold 10,500 shares of the company's stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $9.19, for a total transaction of $96,495.00. Following the completion of the transaction, the insider directly owned 62,278 shares of the company's stock, valued at approximately $572,334.82. The trade was a 14.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 114,158 shares of company stock valued at $1,062,878. Insiders own 2.40% of the company's stock.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Marshall Wace LLP bought a new position in shares of Zevra Therapeutics during the 3rd quarter worth approximately $8,676,000. Rubric Capital Management LP boosted its holdings in Zevra Therapeutics by 60.8% during the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company's stock worth $17,253,000 after purchasing an additional 740,584 shares during the last quarter. Royce & Associates LP bought a new position in Zevra Therapeutics in the third quarter valued at $6,574,000. Adage Capital Partners GP L.L.C. increased its stake in Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company's stock valued at $36,720,000 after buying an additional 550,000 shares during the last quarter. Finally, Nantahala Capital Management LLC increased its stake in Zevra Therapeutics by 34.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company's stock valued at $18,753,000 after buying an additional 500,000 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.